OKYO Pharma Limited (NASDAQ: OKYO) Stock Competitors & Peer Comparison

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, VRTX has a market cap of 132.8B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while VRTX trades at $523.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas VRTX's P/E ratio is 27.53. In terms of profitability, OKYO's ROE is -2.01%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, OKYO is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check VRTX's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, REGN has a market cap of 82.9B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while REGN trades at $805.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas REGN's P/E ratio is 17.64. In terms of profitability, OKYO's ROE is -2.01%, compared to REGN's ROE of +0.14%. Regarding short-term risk, OKYO is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check REGN's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, MRNA has a market cap of 79.9B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while MRNA trades at $200.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas MRNA's P/E ratio is -24.55. In terms of profitability, OKYO's ROE is -2.01%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, OKYO is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for OKYO.Check MRNA's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas VRNA's P/E ratio is -102.80. In terms of profitability, OKYO's ROE is -2.01%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, OKYO is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check VRNA's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, ARGX has a market cap of 54.9B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while ARGX trades at $873.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas ARGX's P/E ratio is 31.50. In terms of profitability, OKYO's ROE is -2.01%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, OKYO is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check ARGX's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas SGEN's P/E ratio is -57.19. In terms of profitability, OKYO's ROE is -2.01%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, OKYO is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check SGEN's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, ONC has a market cap of 40.4B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while ONC trades at $377.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas ONC's P/E ratio is 66.48. In terms of profitability, OKYO's ROE is -2.01%, compared to ONC's ROE of +0.14%. Regarding short-term risk, OKYO is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check ONC's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, RVMDW has a market cap of 40.1B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while RVMDW trades at $9.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas RVMDW's P/E ratio is -1.06. In terms of profitability, OKYO's ROE is -2.01%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, OKYO is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check RVMDW's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, RVMD has a market cap of 40.1B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while RVMD trades at $186.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas RVMD's P/E ratio is -21.22. In terms of profitability, OKYO's ROE is -2.01%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, OKYO is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check RVMD's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, ALNY has a market cap of 30B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while ALNY trades at $224.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas ALNY's P/E ratio is 40.37. In terms of profitability, OKYO's ROE is -2.01%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, OKYO is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check ALNY's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, GMAB has a market cap of 26.9B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while GMAB trades at $43.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas GMAB's P/E ratio is 33.00. In terms of profitability, OKYO's ROE is -2.01%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, OKYO is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for OKYO.Check GMAB's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, ROIV has a market cap of 26.4B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while ROIV trades at $36.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas ROIV's P/E ratio is -34.72. In terms of profitability, OKYO's ROE is -2.01%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, OKYO is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check ROIV's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, UTHR has a market cap of 25.2B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while UTHR trades at $587.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas UTHR's P/E ratio is 21.02. In terms of profitability, OKYO's ROE is -2.01%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, OKYO is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check UTHR's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, INCY has a market cap of 23.5B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while INCY trades at $115.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas INCY's P/E ratio is 15.55. In terms of profitability, OKYO's ROE is -2.01%, compared to INCY's ROE of +0.30%. Regarding short-term risk, OKYO is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check INCY's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, BNTX has a market cap of 22.1B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while BNTX trades at $88.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas BNTX's P/E ratio is -11.43. In terms of profitability, OKYO's ROE is -2.01%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, OKYO is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check BNTX's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, INSM has a market cap of 20.4B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while INSM trades at $93.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas INSM's P/E ratio is -22.72. In terms of profitability, OKYO's ROE is -2.01%, compared to INSM's ROE of -1.11%. Regarding short-term risk, OKYO is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check INSM's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas BGNE's P/E ratio is -22.55. In terms of profitability, OKYO's ROE is -2.01%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, OKYO is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check BGNE's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, OKYO's ROE is -2.01%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, OKYO is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for OKYO.Check DNA-WT's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, EXEL has a market cap of 16.2B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while EXEL trades at $64.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas EXEL's P/E ratio is 18.44. In terms of profitability, OKYO's ROE is -2.01%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, OKYO is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check EXEL's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, ASND has a market cap of 15.2B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while ASND trades at $243.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas ASND's P/E ratio is -100.57. In terms of profitability, OKYO's ROE is -2.01%, compared to ASND's ROE of +1.90%. Regarding short-term risk, OKYO is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check ASND's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, NBIX has a market cap of 14.5B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while NBIX trades at $142.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas NBIX's P/E ratio is 20.62. In terms of profitability, OKYO's ROE is -2.01%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, OKYO is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check NBIX's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, HALO has a market cap of 14.3B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while HALO trades at $125.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas HALO's P/E ratio is 23.44. In terms of profitability, OKYO's ROE is -2.01%, compared to HALO's ROE of +1.81%. Regarding short-term risk, OKYO is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check HALO's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, JAZZ has a market cap of 13.9B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while JAZZ trades at $214.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas JAZZ's P/E ratio is 7.98. In terms of profitability, OKYO's ROE is -2.01%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, OKYO is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check JAZZ's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, BBIO has a market cap of 13.4B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while BBIO trades at $68.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas BBIO's P/E ratio is -18.33. In terms of profitability, OKYO's ROE is -2.01%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, OKYO is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check BBIO's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas KRTX's P/E ratio is -28.09. In terms of profitability, OKYO's ROE is -2.01%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, OKYO is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check KRTX's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, SMMT has a market cap of 12.3B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while SMMT trades at $15.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas SMMT's P/E ratio is -13.81. In terms of profitability, OKYO's ROE is -2.01%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, OKYO is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check SMMT's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while TECH trades at $72.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas TECH's P/E ratio is 37.40. In terms of profitability, OKYO's ROE is -2.01%, compared to TECH's ROE of +0.09%. Regarding short-term risk, OKYO is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check TECH's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas RNAM's P/E ratio is -17.39. In terms of profitability, OKYO's ROE is -2.01%, compared to RNAM's ROE of -0.36%. Regarding short-term risk, OKYO is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check RNAM's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, BMRN has a market cap of 10.8B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while BMRN trades at $55.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas BMRN's P/E ratio is 26.90. In terms of profitability, OKYO's ROE is -2.01%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, OKYO is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check BMRN's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, MDGL has a market cap of 10B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while MDGL trades at $434.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas MDGL's P/E ratio is -33.92. In terms of profitability, OKYO's ROE is -2.01%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, OKYO is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check MDGL's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas RXDX's P/E ratio is -56.47. In terms of profitability, OKYO's ROE is -2.01%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, OKYO is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check RXDX's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, PCVX has a market cap of 9.5B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while PCVX trades at $60.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas PCVX's P/E ratio is -7.92. In terms of profitability, OKYO's ROE is -2.01%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, OKYO is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check PCVX's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, TXG has a market cap of 9.3B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while TXG trades at $71.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas TXG's P/E ratio is -121.02. In terms of profitability, OKYO's ROE is -2.01%, compared to TXG's ROE of -0.09%. Regarding short-term risk, OKYO is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for OKYO.Check TXG's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, KRYS has a market cap of 9.2B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while KRYS trades at $311.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas KRYS's P/E ratio is 39.04. In terms of profitability, OKYO's ROE is -2.01%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, OKYO is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check KRYS's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, TWST has a market cap of 9.2B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while TWST trades at $139.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas TWST's P/E ratio is -62.99. In terms of profitability, OKYO's ROE is -2.01%, compared to TWST's ROE of -0.30%. Regarding short-term risk, OKYO is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for OKYO.Check TWST's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while NUVL trades at $123.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas NUVL's P/E ratio is -21.79. In terms of profitability, OKYO's ROE is -2.01%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, OKYO is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check NUVL's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, KYMR has a market cap of 9.1B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while KYMR trades at $110.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas KYMR's P/E ratio is -34.61. In terms of profitability, OKYO's ROE is -2.01%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, OKYO is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check KYMR's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, CAI has a market cap of 9B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while CAI trades at $32.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas CAI's P/E ratio is 89.91. In terms of profitability, OKYO's ROE is -2.01%, compared to CAI's ROE of +0.19%. Regarding short-term risk, OKYO is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check CAI's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while CRNX trades at $84.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas CRNX's P/E ratio is -16.86. In terms of profitability, OKYO's ROE is -2.01%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, OKYO is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check CRNX's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, PTGX has a market cap of 9B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while PTGX trades at $138.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas PTGX's P/E ratio is 134.40. In terms of profitability, OKYO's ROE is -2.01%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, OKYO is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check PTGX's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas IMGN's P/E ratio is -111.55. In terms of profitability, OKYO's ROE is -2.01%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, OKYO is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check IMGN's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, IBRX has a market cap of 8.7B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while IBRX trades at $8.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas IBRX's P/E ratio is -8.47. In terms of profitability, OKYO's ROE is -2.01%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, OKYO is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check IBRX's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, CYTK has a market cap of 8.5B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while CYTK trades at $61.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas CYTK's P/E ratio is -8.48. In terms of profitability, OKYO's ROE is -2.01%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, OKYO is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check CYTK's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while APGE trades at $135.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas APGE's P/E ratio is -31.19. In terms of profitability, OKYO's ROE is -2.01%, compared to APGE's ROE of -0.30%. Regarding short-term risk, OKYO is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check APGE's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas BPMC's P/E ratio is -51.58. In terms of profitability, OKYO's ROE is -2.01%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, OKYO is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check BPMC's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, SYRE has a market cap of 8.3B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while SYRE trades at $90.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas SYRE's P/E ratio is -46.32. In terms of profitability, OKYO's ROE is -2.01%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, OKYO is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check SYRE's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, TGTX has a market cap of 8.3B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while TGTX trades at $54.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas TGTX's P/E ratio is 19.63. In terms of profitability, OKYO's ROE is -2.01%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, OKYO is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for OKYO.Check TGTX's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, ARWR has a market cap of 8.2B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while ARWR trades at $58.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas ARWR's P/E ratio is -25.79. In terms of profitability, OKYO's ROE is -2.01%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, OKYO is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check ARWR's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas CERE's P/E ratio is -16.47. In terms of profitability, OKYO's ROE is -2.01%, compared to CERE's ROE of -0.72%. Regarding short-term risk, OKYO is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check CERE's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, ABVX has a market cap of 7.7B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while ABVX trades at $88.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas ABVX's P/E ratio is -14.42. In terms of profitability, OKYO's ROE is -2.01%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, OKYO is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check ABVX's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, AXSM has a market cap of 7.6B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while AXSM trades at $145.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas AXSM's P/E ratio is -37.87. In terms of profitability, OKYO's ROE is -2.01%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, OKYO is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for OKYO.Check AXSM's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas MTSR's P/E ratio is -23.58. In terms of profitability, OKYO's ROE is -2.01%, compared to MTSR's ROE of -0.47%. Regarding short-term risk, OKYO is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check MTSR's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, IONS has a market cap of 7.1B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while IONS trades at $42.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas IONS's P/E ratio is -13.13. In terms of profitability, OKYO's ROE is -2.01%, compared to IONS's ROE of -1.11%. Regarding short-term risk, OKYO is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check IONS's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, PRAX has a market cap of 7.1B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while PRAX trades at $252.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas PRAX's P/E ratio is -19.56. In terms of profitability, OKYO's ROE is -2.01%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, OKYO is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check PRAX's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas MRUS's P/E ratio is -17.05. In terms of profitability, OKYO's ROE is -2.01%, compared to MRUS's ROE of -0.31%. Regarding short-term risk, OKYO is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check MRUS's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas ACLX's P/E ratio is -28.27. In terms of profitability, OKYO's ROE is -2.01%, compared to ACLX's ROE of -0.40%. Regarding short-term risk, OKYO is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check ACLX's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas RETA's P/E ratio is -66.29. In terms of profitability, OKYO's ROE is -2.01%, compared to RETA's ROE of +0.47%. Regarding short-term risk, OKYO is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check RETA's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, IOVA has a market cap of 6.4B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while IOVA trades at $14.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas IOVA's P/E ratio is -19.30. In terms of profitability, OKYO's ROE is -2.01%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, OKYO is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for OKYO.Check IOVA's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas CNTA's P/E ratio is -22.63. In terms of profitability, OKYO's ROE is -2.01%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, OKYO is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check CNTA's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, RYTM has a market cap of 6.1B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while RYTM trades at $89.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas RYTM's P/E ratio is -28.70. In terms of profitability, OKYO's ROE is -2.01%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, OKYO is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check RYTM's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, TERN has a market cap of 6.1B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas TERN's P/E ratio is -51.41. In terms of profitability, OKYO's ROE is -2.01%, compared to TERN's ROE of -0.14%. Regarding short-term risk, OKYO is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check TERN's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, LGND has a market cap of 6.1B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while LGND trades at $303.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas LGND's P/E ratio is 33.32. In terms of profitability, OKYO's ROE is -2.01%, compared to LGND's ROE of +0.20%. Regarding short-term risk, OKYO is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check LGND's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, BLTE has a market cap of 5.9B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while BLTE trades at $147.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas BLTE's P/E ratio is -78.79. In terms of profitability, OKYO's ROE is -2.01%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, OKYO is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check BLTE's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, IMVT has a market cap of 5.9B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while IMVT trades at $28.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas IMVT's P/E ratio is -10.07. In terms of profitability, OKYO's ROE is -2.01%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, OKYO is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check IMVT's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, MANE has a market cap of 5.8B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while MANE trades at $138.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas MANE's P/E ratio is -44.30. In terms of profitability, OKYO's ROE is -2.01%, compared to MANE's ROE of -0.38%. Regarding short-term risk, OKYO is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check MANE's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas CDTX's P/E ratio is -19.77. In terms of profitability, OKYO's ROE is -2.01%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, OKYO is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check CDTX's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, OKYO's ROE is -2.01%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, OKYO is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check ABCM's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas ISEE's P/E ratio is -22.44. In terms of profitability, OKYO's ROE is -2.01%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, OKYO is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check ISEE's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, KOD has a market cap of 5.5B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while KOD trades at $87.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas KOD's P/E ratio is -21.01. In terms of profitability, OKYO's ROE is -2.01%, compared to KOD's ROE of -2.73%. Regarding short-term risk, OKYO is less volatile compared to KOD. This indicates lower risk in terms of short-term price fluctuations for OKYO.Check KOD's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, CGON has a market cap of 5.5B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while CGON trades at $61.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas CGON's P/E ratio is -22.94. In terms of profitability, OKYO's ROE is -2.01%, compared to CGON's ROE of -0.25%. Regarding short-term risk, OKYO is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check CGON's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, COGT has a market cap of 5.4B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while COGT trades at $31.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas COGT's P/E ratio is -14.79. In terms of profitability, OKYO's ROE is -2.01%, compared to COGT's ROE of -0.73%. Regarding short-term risk, OKYO is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check COGT's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, ORKA has a market cap of 5.3B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while ORKA trades at $80.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas ORKA's P/E ratio is -41.31. In terms of profitability, OKYO's ROE is -2.01%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, OKYO is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check ORKA's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas APLS's P/E ratio is 38.35. In terms of profitability, OKYO's ROE is -2.01%, compared to APLS's ROE of +0.40%. Regarding short-term risk, OKYO is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check APLS's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, MIRM has a market cap of 5.2B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while MIRM trades at $80.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas MIRM's P/E ratio is -5.53. In terms of profitability, OKYO's ROE is -2.01%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, OKYO is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check MIRM's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, PTCT has a market cap of 5.1B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while PTCT trades at $60.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas PTCT's P/E ratio is -26.00. In terms of profitability, OKYO's ROE is -2.01%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, OKYO is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for OKYO.Check PTCT's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, SRRK has a market cap of 5.1B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while SRRK trades at $41.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas SRRK's P/E ratio is -12.03. In terms of profitability, OKYO's ROE is -2.01%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, OKYO is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check SRRK's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, ERAS has a market cap of 5B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while ERAS trades at $14.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas ERAS's P/E ratio is -15.47. In terms of profitability, OKYO's ROE is -2.01%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, OKYO is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for OKYO.Check ERAS's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, DFTX has a market cap of 4.8B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while DFTX trades at $35.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas DFTX's P/E ratio is N/A. In terms of profitability, OKYO's ROE is -2.01%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, OKYO is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check DFTX's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, CRSP has a market cap of 4.8B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while CRSP trades at $49.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas CRSP's P/E ratio is -10.38. In terms of profitability, OKYO's ROE is -2.01%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, OKYO is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check CRSP's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, TVTX has a market cap of 4.7B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while TVTX trades at $50.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas TVTX's P/E ratio is -111.22. In terms of profitability, OKYO's ROE is -2.01%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, OKYO is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check TVTX's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas FOLD's P/E ratio is -161.00. In terms of profitability, OKYO's ROE is -2.01%, compared to FOLD's ROE of -0.02%. Regarding short-term risk, OKYO is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check FOLD's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas AKRO's P/E ratio is -14.57. In terms of profitability, OKYO's ROE is -2.01%, compared to AKRO's ROE of -0.15%. Regarding short-term risk, OKYO is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check AKRO's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas ALPN's P/E ratio is -101.52. In terms of profitability, OKYO's ROE is -2.01%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, OKYO is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check ALPN's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, DNTH has a market cap of 4.3B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while DNTH trades at $76.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas DNTH's P/E ratio is -18.50. In terms of profitability, OKYO's ROE is -2.01%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, OKYO is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check DNTH's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas OPT's P/E ratio is -1.52. In terms of profitability, OKYO's ROE is -2.01%, compared to OPT's ROE of +1.18%. Regarding short-term risk, OKYO is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check OPT's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while PRTC trades at $17.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas PRTC's P/E ratio is -3.78. In terms of profitability, OKYO's ROE is -2.01%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, OKYO is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check PRTC's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, EWTX has a market cap of 4.2B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while EWTX trades at $39.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas EWTX's P/E ratio is -21.25. In terms of profitability, OKYO's ROE is -2.01%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, OKYO is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check EWTX's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas MRTX's P/E ratio is -4.82. In terms of profitability, OKYO's ROE is -2.01%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, OKYO is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check MRTX's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, ADPT has a market cap of 4.1B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while ADPT trades at $25.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas ADPT's P/E ratio is -62.22. In terms of profitability, OKYO's ROE is -2.01%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, OKYO is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for OKYO.Check ADPT's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, RLAY has a market cap of 4B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while RLAY trades at $18.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas RLAY's P/E ratio is -11.58. In terms of profitability, OKYO's ROE is -2.01%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, OKYO is more volatile compared to RLAY. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check RLAY's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, TNGX has a market cap of 3.9B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while TNGX trades at $23.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas TNGX's P/E ratio is -28.12. In terms of profitability, OKYO's ROE is -2.01%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, OKYO is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for OKYO.Check TNGX's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, ARQT has a market cap of 3.9B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while ARQT trades at $31.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas ARQT's P/E ratio is 148.57. In terms of profitability, OKYO's ROE is -2.01%, compared to ARQT's ROE of +0.15%. Regarding short-term risk, OKYO is more volatile compared to ARQT. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check ARQT's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while CPRX trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas CPRX's P/E ratio is 17.49. In terms of profitability, OKYO's ROE is -2.01%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, OKYO is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check CPRX's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, ABCL has a market cap of 3.8B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while ABCL trades at $11.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas ABCL's P/E ratio is -21.89. In terms of profitability, OKYO's ROE is -2.01%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, OKYO is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for OKYO.Check ABCL's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas RYZB's P/E ratio is -57.86. In terms of profitability, OKYO's ROE is -2.01%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, OKYO is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check RYZB's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas CBAY's P/E ratio is -32.81. In terms of profitability, OKYO's ROE is -2.01%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, OKYO is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check CBAY's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, LEGN has a market cap of 3.6B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while LEGN trades at $19.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas LEGN's P/E ratio is -28.34. In terms of profitability, OKYO's ROE is -2.01%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, OKYO is more volatile compared to LEGN. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check LEGN's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas SWTX's P/E ratio is -13.78. In terms of profitability, OKYO's ROE is -2.01%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, OKYO is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check SWTX's competition here

OKYO Pharma Limited (NASDAQ: OKYO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OKYO stands at 73.5M. In comparison, XENE has a market cap of 3.4B. Regarding current trading prices, OKYO is priced at $1.40 on the NASDAQ, while XENE trades at $35.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OKYO currently has a P/E ratio of -27.89, whereas XENE's P/E ratio is -7.52. In terms of profitability, OKYO's ROE is -2.01%, compared to XENE's ROE of -0.44%. Regarding short-term risk, OKYO is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for OKYO.Check XENE's competition here